Payers, Pension Plans, Pharmacies Ask FDA Not To Give Unique Names To Biosimilars

JD
Jones Day

Contributor

Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
Earlier this month, a group of 32 companies and organizations urged FDA not to require distinct names for biosimilar products
United States Food, Drugs, Healthcare, Life Sciences

Earlier this month, a group of 32 companies and organizations, including health insurers, pharmacies, labor unions, and pension plans, urged FDA not to require distinct names for biosimilar products, explaining that such a policy would undermine the potential cost savings generated by such generic products—which are predicted to be as much as $100 billion over the first 10 years of biosimilar market formation.

In its letter to Commissioner Margaret Hamburg, the group argues that biologics and biosimilars should be required to have the same International Nonproprietary Name ("INN") in order to reduce provider and patient confusion and to promote swift uptake of biosimilar products when they come to market. Although no such products are currently sold in the United States, the group claims if biosimilars are marketed under unique names, then individuals might fail to recognize them as substitutes for brand-name biologics, which could stifle their use and hence undermine cost savings. The group also argues that using unique INNs would also disconnect biosimilars from existing safety information about their underlying molecules.

The Biologics Price Competition and Innovation Act of 2009 established a regulatory pathway for approving biosimilars, but FDA has yet to specify a naming policy for this category of products.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More